xylyx

Pathological ECM changes drive disease progression by regulating cell–matrix interactions. Human diseased ECM substrates, including fibrotic liver and lung ECMs, enable clinically-relevant, high-fidelity disease modeling predictive of human disease biology.

Related Resources

Application Note: Accelerating Antifibrotic Drug Development with Human Fibrotic Liver ECM Substrates
Application Note: Accelerating Antifibrotic Drug Development with Human Fibrotic Lung ECM Substrates
Publication: Fibrotic Human Lung Extracellular Matrix as a Disease-Specific Substrate for Models of Pulmonary Fibrosis (2019)
Poster: Fibrotic Liver Extracellular Matrix Substrates for 3D in-vitro Models of Human Liver Fibrosis
Poster: Fibrotic Lung Extracellular Matrix Substrates for 3D in-vitro Models of Human Pulmonary Fibrosis
Webinar: Transforming Lung Fibrosis Drug Discovery with The IN MATRICO® Human Lung Fibrosis Platform